AMRX logo

Amneal Pharmaceuticals (AMRX) Cash from operations

annual CFO:

$295.10M-$50.48M(-14.61%)
December 31, 2024

Summary

  • As of today (May 29, 2025), AMRX annual cash flow from operations is $295.10 million, with the most recent change of -$50.48 million (-14.61%) on December 31, 2024.
  • During the last 3 years, AMRX annual CFO has risen by +$53.28 million (+22.03%).
  • AMRX annual CFO is now -22.14% below its all-time high of $379.00 million, reached on December 31, 2020.

Performance

1-year change

-14.61%

3-year change

+22.03%

5-year change

+17207.86%

15-year change

+26.01%

AMRX Cash from operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

90.88%
AMRX annual cash flow from operations is higher than 90.88% of companies in Healthcare sector

Range

All-time high

$379.00M
AMRX annual cash flow from operations is currently -22.14% below its historical high of $379.00 million

3-year low

$65.10M
AMRX annual cash flow from operations is currently +353.30% above its 3-year low

Earnings dates

Last annual earnings report date

Dec 31, 2024
AMRX previous annual earnings announcement was published on Dec 31, 2024

Next annual earnings report date

N/A
AMRX next annual earnings announcement has not yet been scheduled

OtherAMRXcash flow metrics

annual CFI

-$63.00M
AMRX annual cash flow from investing activities is -$63.00 million

annual CFF

-$211.79M
AMRX annual cash flow from financing activities is -$211.79 million

annual FCF

$220.11M
AMRX annual free cash flow is $220.11 million

annual CAPEX

$74.99M
AMRX annual capital expenditures is $74.99 million

quarterly CFO:

$7.41M-$110.67M(-93.73%)
March 31, 2025

Summary

  • As of today (May 29, 2025), AMRX quarterly cash flow from operations is $7.41 million, with the most recent change of -$110.67 million (-93.73%) on March 31, 2025.
  • Over the past year, AMRX quarterly CFO has increased by +$11.82 million (+267.98%).
  • AMRX quarterly CFO is now -97.15% below its all-time high of $259.65 million, reached on December 31, 2018.

Performance

3-month change

-93.73%

1-year change

+267.98%

3-year change

-93.84%

5-year change

-84.89%

AMRX quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

83.1%
AMRX quarterly cash flow from operations is higher than 83.1% of companies in Healthcare sector

Range

All-time high

$259.65M
AMRX quarterly cash flow from operations is currently -97.15% below its historical high of $259.65 million

3-year low

-$125.52M

Earnings dates

Last quarterly earnings report date

Mar 31, 2025
AMRX previous earnings announcement was published on Mar 31, 2025

Next quarterly earnings report date

Aug 8, 2025
AMRX next earnings announcement is scheduled for Aug 8, 2025

OtherAMRXcash flow metrics

quarterly CFI

-$17.80M
AMRX quarterly cash flow from investing activities is -$17.80 million

quarterly CFF

-$39.17M
AMRX quarterly cash flow from financing activities is -$39.17 million

quarterly FCF

-$10.91M
AMRX quarterly free cash flow is -$10.91 million

quarterly CAPEX

$18.32M
AMRX quarterly capital expenditures is $18.32 million

TTM CFO:

$306.92M+$11.82M(+4.00%)
March 31, 2025

Summary

  • As of today (May 29, 2025), AMRX TTM cash flow from operations is $306.92 million, with the most recent change of +$11.82 million (+4.00%) on March 31, 2025.
  • Over the past year, AMRX TTM CFO has increased by +$105.46 million (+52.35%).
  • AMRX TTM CFO is now -35.81% below its all-time high of $478.10 million, reached on March 31, 2021.

Performance

3-month change

+4%

1-year change

+52.35%

3-year change

+43.4%

5-year change

+92.86%

AMRX TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

90.51%
AMRX TTM cash flow from operations is higher than 90.51% of companies in Healthcare sector

Range

All-time high

$478.10M
AMRX TTM cash flow from operations is currently -35.81% below its historical high of $478.10 million

3-year low

$65.10M
AMRX TTM cash flow from operations is currently +371.45% above its 3-year low

Earnings dates

Last quarterly earnings report date

Mar 31, 2025
AMRX previous earnings announcement was published on Mar 31, 2025

Next quarterly earnings report date

Aug 8, 2025
AMRX next earnings announcement is scheduled for Aug 8, 2025

OtherAMRXcash flow metrics

TTM CFI

-$61.03M
AMRX TTM cash flow from investing activities is -$61.03 million

TTM CFF

-$227.80M
AMRX TTM cash flow from financing activities is -$227.80 million

TTM FCF

$233.37M
AMRX TTM free cash flow is $233.37 million

TTM CAPEX

$73.55M
AMRX TTM capital expenditures is $73.55 million

Cash from operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

AMRX Cash from operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-14.6%+268.0%+52.4%
3 y3 years+22.0%-93.8%+43.4%
5 y5 years+10000.0%-84.9%+92.9%

AMRX Cash from operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-14.6%+353.3%-94.8%+105.9%-11.2%+371.4%
5 y5-year-22.1%>+9999.0%-95.9%+105.9%-35.8%+371.4%
alltimeall time-22.1%>+9999.0%-97.2%+105.9%-35.8%+529.0%

AMRX Cash from operations History

DateAnnualQuarterlyTTM
Mar 2025
-
$7.41M(-93.7%)
$306.92M(+4.0%)
Dec 2024
$295.10M(-14.6%)
$118.08M(-16.7%)
$295.10M(-5.7%)
Sep 2024
-
$141.77M(+257.5%)
$312.84M(+23.9%)
Jun 2024
-
$39.66M(-999.3%)
$252.46M(+25.3%)
Mar 2024
-
-$4.41M(-103.2%)
$201.46M(-41.7%)
Dec 2023
$345.58M(+430.8%)
$135.82M(+66.9%)
$345.58M(+85.3%)
Sep 2023
-
$81.39M(-817.4%)
$186.46M(-6.1%)
Jun 2023
-
-$11.35M(-108.1%)
$198.65M(+135.2%)
Mar 2023
-
$139.71M(-699.8%)
$84.47M(+29.8%)
Dec 2022
$65.10M(-73.1%)
-$23.29M(-124.9%)
$65.10M(-57.1%)
Sep 2022
-
$93.57M(-174.5%)
$151.65M(+8.0%)
Jun 2022
-
-$125.52M(-204.3%)
$140.45M(-34.4%)
Mar 2022
-
$120.34M(+90.2%)
$214.03M(-11.5%)
Dec 2021
$241.82M
$63.26M(-23.2%)
$241.82M(-15.0%)
Sep 2021
-
$82.36M(-258.6%)
$284.52M(+15.2%)
DateAnnualQuarterlyTTM
Jun 2021
-
-$51.93M(-135.1%)
$246.93M(-48.4%)
Mar 2021
-
$148.13M(+39.8%)
$478.10M(+26.1%)
Dec 2020
$379.00M(>+9900.0%)
$105.96M(+136.6%)
$379.00M(+70.6%)
Sep 2020
-
$44.78M(-75.0%)
$222.15M(-30.0%)
Jun 2020
-
$179.24M(+265.6%)
$317.29M(+99.4%)
Mar 2020
-
$49.03M(-196.3%)
$159.14M(+9233.8%)
Dec 2019
$1.71M(-99.3%)
-$50.89M(-136.4%)
$1.71M(-99.5%)
Sep 2019
-
$139.91M(+563.3%)
$312.25M(+33.2%)
Jun 2019
-
$21.09M(-119.5%)
$234.46M(+104.3%)
Mar 2019
-
-$108.41M(-141.8%)
$114.79M(-54.1%)
Dec 2018
$250.23M(+6.9%)
$259.65M(+317.9%)
$250.23M(-2756.1%)
Sep 2018
-
$62.13M(-163.0%)
-$9.42M(-86.8%)
Jun 2018
-
-$98.58M(-464.7%)
-$71.55M(-364.7%)
Mar 2018
-
$27.03M
$27.03M
Dec 2017
$234.19M(+103.5%)
-
-
Dec 2016
$115.06M
-
-

FAQ

  • What is Amneal Pharmaceuticals annual cash flow from operations?
  • What is the all time high annual CFO for Amneal Pharmaceuticals?
  • What is Amneal Pharmaceuticals annual CFO year-on-year change?
  • What is Amneal Pharmaceuticals quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Amneal Pharmaceuticals?
  • What is Amneal Pharmaceuticals quarterly CFO year-on-year change?
  • What is Amneal Pharmaceuticals TTM cash flow from operations?
  • What is the all time high TTM CFO for Amneal Pharmaceuticals?
  • What is Amneal Pharmaceuticals TTM CFO year-on-year change?

What is Amneal Pharmaceuticals annual cash flow from operations?

The current annual CFO of AMRX is $295.10M

What is the all time high annual CFO for Amneal Pharmaceuticals?

Amneal Pharmaceuticals all-time high annual cash flow from operations is $379.00M

What is Amneal Pharmaceuticals annual CFO year-on-year change?

Over the past year, AMRX annual cash flow from operations has changed by -$50.48M (-14.61%)

What is Amneal Pharmaceuticals quarterly cash flow from operations?

The current quarterly CFO of AMRX is $7.41M

What is the all time high quarterly CFO for Amneal Pharmaceuticals?

Amneal Pharmaceuticals all-time high quarterly cash flow from operations is $259.65M

What is Amneal Pharmaceuticals quarterly CFO year-on-year change?

Over the past year, AMRX quarterly cash flow from operations has changed by +$11.82M (+267.98%)

What is Amneal Pharmaceuticals TTM cash flow from operations?

The current TTM CFO of AMRX is $306.92M

What is the all time high TTM CFO for Amneal Pharmaceuticals?

Amneal Pharmaceuticals all-time high TTM cash flow from operations is $478.10M

What is Amneal Pharmaceuticals TTM CFO year-on-year change?

Over the past year, AMRX TTM cash flow from operations has changed by +$105.46M (+52.35%)
On this page